Background: Ischemic reperfusion injury of kidney is major cause for renal failure, however the involved pathogenesis remains unclear creating an void for its effective treatment. Here we studied involvement of microRNA-424 in renal injury.
Methods: For the study, p53 or HIF-1α mice were used, ischemic renal injury was induced using clamping of renal pedicles bilateraly. Proximal kidney tubular cells were used for studies. Hoechst 33342 analysis was done for apoptosis. Blood urea nitrogen (BUN) and serum creatinine was done for renal function, Hematoxylin-eosin tissue damage and Terminal transferase-dUTP nick-end labeling assay for apoptosis. RT-PCR was done for miRNA and ChIP assay to identify the binding of p53 to miR-424. TargetScan and miRanda data base were scanned to find targets of miR-424. Protein expression was done by western blot analysis.
Results: We discovered that, miR-424 was over-expressed in ischemic renal injury mice and in hypoxia exposed renal cells. In cells, miR-424 suppressed the expression levels of death receptor 6 (DR6) and halted the apoptosis mediated by hypoxia. Blocking of miR-424 halted the inhibition of DR6 and caused apoptosis and activation of caspase. In mice, miR-424 mimic inhibited expression of DR6 and attenuated ischemic renal injury. We established that, up-regulation of miR-424 in ischemic reperfusion injury was p53 dependent, also inhibition of p53 caused repression of miR-424 levels in hypoxia induced cells . The p53 knockout mice showed attenuation in levels of miR-424 confirming role of p53 behind up-regulation of miR-424 .
Conclusion: The study confirmed p53/miR-424/DR6 as a protective cascade during ischemic-reperfusion injury.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511784 | PMC |
Pharmaceutics
December 2024
Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China.
SPT-07A, a D-borneol, is currently being developed in China for the treatment of ischemic stroke. We aimed to create a whole-body physiologically-based pharmacokinetic (PBPK) model to predict the pharmacokinetics of SPT-07A in rats, dogs, and humans. The in vitro metabolism of SPT-07A was studied using hepatic, renal, and intestinal microsomes.
View Article and Find Full Text PDFMedicina (Kaunas)
December 2024
Department Cardiovascular Surgery, Gazi University Faculty of Medicine, Ankara 06560, Turkey.
Ischemia-reperfusion (I/R) injury is a process in which impaired perfusion is restored by restoring blood flow and tissue recirculation. Nanomedicine uses cutting-edge technologies that emerge from interdisciplinary influences. In the literature, there are very few in vivo and in vitro studies on how cerium oxide (CeO) affects systemic anti-inflammatory response and inflammation.
View Article and Find Full Text PDFJ Clin Med
December 2024
Department of Cardiology and Internal Medicine with Cardiac Intensive Care Unit, Medical University of Białystok, ul. M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland.
Lower Extremity Artery Disease (LEAD) is a predictor of atherosclerotic plaques in other locations and significantly increases the risk of death from cardiovascular events. This study aimed to identify cardiology patient subpopulations that should undergo Ankle-Brachial Index (ABI) measurement. A total of 800 patients hospitalized in the Department of Cardiology were included.
View Article and Find Full Text PDFJ Clin Med
December 2024
Department of Anesthesiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
The development of inhaled anesthetics (IAs) has a rich history dating back many centuries. In modern times they have played a pivotal role in anesthesia and critical care by allowing deep sedation during periods of critical illness and surgery. In addition to their sedating effects, they have many systemic effects allowing for therapy beyond surgical anesthesia.
View Article and Find Full Text PDFBioengineering (Basel)
December 2024
Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan.
To elucidate the unidentified roles of a selective peroxisome proliferator-activated receptor α (PPARα) agonist, pemafibrate (Pema), on the pathogenesis of retinal ischemic diseases (RID)s, the pharmacological effects of Pema on the retinal pigment epithelium (RPE), which is involved in the pathogenesis of RID, were compared with the pharmacological effects of the non-fibrate PPARα agonist GW7647 (GW). For this purpose, the human RPE cell line ARPE19 that was untreated (NT) or treated with Pema or GW was subjected to Seahorse cellular metabolic analysis and RNA sequencing analysis. Real-time cellular metabolic function analysis revealed that pharmacological effects of the PPARα agonist actions on essential metabolic functions in RPE cells were substantially different between Pema-treated cells and GW-treated cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!